Literature DB >> 16940130

Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases.

Niklas Lindegardh1, Geraint R Davies, Tinh Hien Tran, Jeremy Farrar, Pratap Singhasivanon, Nicholas P J Day, Nicholas J White.   

Abstract

The anti-influenza drug oseltamivir is an ester prodrug activated by hepatic carboxylesterases. Plasma esterases also convert up to 31.8% of the parent compound to the active metabolite after 4 h ex vivo, with wide interindividual variation. This source of error is removed by adding the esterase inhibitor dichlorvos to blood collection tubes.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940130      PMCID： PMC1563560          DOI： 10.1128/AAC.00500-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

2.  Aetiology of prolonged apnoea after suxamethonium.

Authors:  H W Bauld; P F Gibson; P J Jebson; S S Brown
Journal:  Br J Anaesth       Date:  1974-04       Impact factor: 9.166

3.  Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.

Authors:  C Oo; J Barrett; G Hill; J Mann; A Dorr; R Dutkowski; P Ward
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate.

Authors:  Paul Snell; Nisha Dave; Katie Wilson; Lucy Rowell; Angelica Weil; Lawrence Galitz; Richard Robson
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

5.  Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample.

Authors:  Ricardo L R Souza; Liya R Mikami; Rodrigo O B Maegawa; Eleidi A Chautard-Freire-Maia
Journal:  Mol Genet Metab       Date:  2005-01-24       Impact factor: 4.797

6.  Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

Authors:  H Wiltshire; B Wiltshire; A Citron; T Clarke; C Serpe; D Gray; W Herron
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-08-18

Review 7.  Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

Authors:  Penelope Ward; Ian Small; James Smith; Pia Suter; Regina Dutkowski
Journal:  J Antimicrob Chemother       Date:  2005-02       Impact factor: 5.790

8.  Biochemical properties of blood esmolol esterase.

Authors:  C Y Quon; H F Stampfli
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

9.  Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italian-population study.

Authors:  Giuliana Lando; Andrea Mosca; Roberto Bonora; Franco Azzario; Silvana Penco; Alessandro Marocchi; Mauro Panteghini; Maria Cristina Patrosso
Journal:  Pharmacogenetics       Date:  2003-05

10.  Vaccines and antiviral drugs in pandemic preparedness.

Authors:  Arnold S Monto
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883
View more
  15 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.

Authors:  Susan M Abdel-Rahman; Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

3.  Importance of collection tube during clinical studies of oseltamivir.

Authors:  Niklas Lindegardh; Geraint R Davies; Tran Tinh Hien; Jeremy Farrar; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

4.  Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.

Authors:  Mototsugu Ito; Hiroyuki Kusuhara; Atsushi Ose; Tsunenori Kondo; Kazunari Tanabe; Hideki Nakayama; Shigeru Horita; Takuya Fujita; Yuichi Sugiyama
Journal:  AAPS J       Date:  2016-10-31       Impact factor: 4.009

5.  Effects of alcohol on human carboxylesterase drug metabolism.

Authors:  Robert B Parker; Zhe-Yi Hu; Bernd Meibohm; S Casey Laizure
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

6.  Heat stabilization of blood spot samples for determination of metabolically unstable drug compounds.

Authors:  Daniel Blessborn; Karl Sköld; David Zeeberg; Karnrawee Kaewkhao; Olof Sköld; Martin Ahnoff
Journal:  Bioanalysis       Date:  2013-01       Impact factor: 2.681

7.  Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

Authors:  Y Wattanagoon; K Stepniewska; N Lindegårdh; S Pukrittayakamee; U Silachamroon; W Piyaphanee; T Singtoroj; W Hanpithakpong; G Davies; J Tarning; W Pongtavornpinyo; C Fukuda; P Singhasivanon; N P J Day; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

8.  Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

Authors:  Mark Holodniy; Scott R Penzak; Timothy M Straight; Richard T Davey; Kelvin K Lee; Matthew Bidwell Goetz; Dennis W Raisch; Francesca Cunningham; Emil T Lin; Noemi Olivo; Lawrence R Deyton
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

9.  Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats.

Authors:  Chia-Chun Lin; Jiin-Cherng Yen; Yu-Tse Wu; Lie-Chwen Lin; Tung-Hu Tsai
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

10.  Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.

Authors:  Gero P Hooff; Roland J W Meesters; Jeroen J A van Kampen; Nick A van Huizen; Birgit Koch; Asmar F Y Al Hadithy; Teun van Gelder; Albert D M E Osterhaus; Rob A Gruters; Theo M Luider
Journal:  Anal Bioanal Chem       Date:  2011-05-03       Impact factor: 4.142
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.